Meeting
2012 ASCO Annual Meeting
Comparison of two doses of cabazitaxel plus prednisone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel (D)-containing regimen.
Authors
Mario A. Eisenberger
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, James Buchanan Brady Urological Institute, Baltimore, MD
Mario A. Eisenberger , Anne-Claire Hardy-Bessard , Loic Mourey , Paul N. Mainwaring , Daniel Ford , Jeremy David Shapiro , Joan Carles , Siobhan Ng , Thierry Gil , Boris Alekseev , Sergey Ivanov , Thomas Facchini , Eric Legouffe , Oleg Apolikhin , Hardev S. Pandha , Aart Beeker , Oleg Karyakin , Wendy Zhang , Mustapha Chadjaa , Johann Sebastian De Bono
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer
Track
Genitourinary Cancer
Sub Track
Prostate Cancer
Clinical Trial Registration Number
NCT01308580
Citation
J Clin Oncol 30, 2012 (suppl; abstr TPS4692^)
Abstract #
TPS4692^
Poster Bd #
16C
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
PROSELICA study update: Comparison of two doses of cabazitaxel (Cbz) plus prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel (D)-containing regimen.
First Author: Mario A. Eisenberger
Poster
2023 ASCO Genitourinary Cancers Symposium
![Efficacy of systemic therapy following [<sup>177</sup>Lu] Lu-PSMA in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).](https://d201v5jt9ylckg.cloudfront.net/298/15164/217588/217588_A228_poster_pv.jpg)
Efficacy of systemic therapy following [177Lu] Lu-PSMA in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Louise Kathleen Kostos
Poster
2021 ASCO Annual Meeting
First results from a randomized phase II study of cabazitaxel (CBZ) versus an androgen receptor targeted agent (ARTA) in patients with poor-prognosis castration-resistant prostate cancer (mCRPC).
First Author: Kim van der Zande
Poster
2018 Genitourinary Cancers Symposium
Impact of new systemic therapies on overall survival (OS) of patients (pts) with metastatic castration resistant prostate cancer (mCRPC) in a hospital-based registry.
First Author: Edoardo Francini